Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GWLKW
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
121G12-CysMab-DAPA-MPET-DM4
|
|||||
| Synonyms |
121G12 CysMab DAPA MPET DM4
Click to Show/Hide
|
|||||
| Organization |
Novartis AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
3.8
|
|||||
| Antibody Name |
Anti-CCR7 mAb 121G12
|
Antibody Info | ||||
| Antigen Name |
C-C chemokine receptor type 7 (CCR7)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
121G12.CysMab.DAPA.MPET.DM4 linker
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≍ 10.70% (Day 28) | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
All treatments were conducted by, i.v, 1 mg/kg (day1 and day15) injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | OCI-LY3 CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | OCI-Ly3 cells | CVCL_8800 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≍ 20.60% (Day 20) | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
All treatments were conducted by, i.v, 5 mg/kg (day1 and day15) injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | Toledo CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | Toledo cells | CVCL_3611 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≉ 33.00% (Day 9) | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
All treatments were conducted at day 0 by a single dose, i.v, 2 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | KE97 CDX model | ||||
| In Vitro Model | Normal | KE-97 cells | CVCL_3386 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≍ 52.70% (Day 20) | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
All treatments were conducted by, i.v, 2 mg/kg (day1 and day15) injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | Toledo CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | Toledo cells | CVCL_3611 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≊ 54.00% (Day 9) | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
All treatments were conducted at day 0 by a single dose, i.v, 5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | KE97 CDX model | ||||
| In Vitro Model | Normal | KE-97 cells | CVCL_3386 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≍ 74.60% (Day 28) | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
All treatments were conducted by, i.v, 0.5 mg/kg (day1 and day15) injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | OCI-LY3 CDX model | ||||
| In Vitro Model | Diffuse large B-cell lymphoma | OCI-Ly3 cells | CVCL_8800 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 78.62% (Day 9) | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
All treatments were conducted at day 0 by a single dose, i.v, 0.5 mg/kg x1 injection into the tail vein, Data, depicted as mean tumour volume, consists of 6-8 animals per experimental group.
|
||||
| In Vivo Model | KE97 CDX model | ||||
| In Vitro Model | Normal | KE-97 cells | CVCL_3386 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 1.69 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Hodgkin lymphoma | SUP-HD1 cells | CVCL_2208 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.17 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Normal | KE-97 cells | CVCL_3386 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.24 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Normal | KE-97 cells | CVCL_3386 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.28 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Anaplastic large cell lymphoma | DEL cells | CVCL_1170 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.29 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Anaplastic large cell lymphoma | DEL cells | CVCL_1170 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 2.94 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Hodgkin lymphoma | L-540 cells | CVCL_1362 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.24 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | T-cell large granular lymphocyte leukemia | MOTN-1 cells | CVCL_2127 | ||
| Experiment 8 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.62 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Mantle cell lymphoma | JVM-2 cells | CVCL_1319 | ||
| Experiment 9 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 4.90 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Hodgkin lymphoma | L-540 cells | CVCL_1362 | ||
| Experiment 10 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.61 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Anaplastic large cell lymphoma | DEL cells | CVCL_1170 | ||
| Experiment 11 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 6.42 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | OCI-Ly3 cells | CVCL_8800 | ||
| Experiment 12 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 20.00 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | Chronic lymphocytic leukemia | MEC-2 cells | CVCL_1871 | ||
| Experiment 13 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 20.00 nM | Positive CCR7 expression (CCR7+++/++) | ||
| Method Description |
Target expressing or non-expressing cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e, no antibody conjugated to the drug) in duplicate at 10 concentrations. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation MTS Assay.
Click to Show/Hide
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Peer cells | CVCL_1913 | ||